{"filings":[{"id":1304920,"accession_number":"0001193125-26-285572","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K/A","filed_at":"2026-06-26T20:31:01+00:00","items":["3.03"],"status":"ready","headline":"Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.","Certificate of Amendment filed with Delaware; effective 11:59 pm ET June 29.","Shares trade split-adjusted on Nasdaq starting June 30; new CUSIP 22053A305.","Outstanding shares reduce from ~19.56M to ~0.98M; fractional shares rounded up.","All options and warrants proportionally adjusted; Equiniti Trust acts as exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1287596,"accession_number":"0001193125-26-284089","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-06-26T13:18:21+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.","Certificate of Amendment filed with Delaware Secretary of State on June 26, 2026; effective June 29 at 11:59 pm ET.","Pre-split shares outstanding: 19,559,257; post-split approx 977,963; CUSIP changes to 22053A305.","Ticker remains QNCX; options and warrants proportionally adjusted; fractional shares cashed out."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1002237,"accession_number":"0001193125-26-267862","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-06-11T21:06:44+00:00","items":["5.07"],"status":"ready","headline":"Quince Therapeutics stockholders approve reverse stock split at 1:10 to 1:100 ratio","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split approved with 4,715,574 for, 1,517,896 against, 21,866 abstentions.","Board authorized to determine timing and exact ratio within 1-for-10 to 1-for-100 range.","Class I director June Bray elected with 2,430,964 votes for, 216,735 withheld; 3,607,640 broker non-votes.","BDO USA, P.C. ratified as independent auditor for FY2026 with 6,080,608 votes for.","Advisory vote on executive compensation approved with 2,504,778 for, 116,876 against, 26,044 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584077,"accession_number":"0001193125-26-234858","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-05-21T21:06:52+00:00","items":["8.01"],"status":"ready","headline":"Quince Therapeutics regains Nasdaq listing compliance via equity alternative","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company had been notified of MVLS deficiency on March 17, 2026.","On May 20, 2026, Staff confirmed compliance based on Q1 2026 stockholders' equity of $15.672M under Rule 5450(b)(1)(A).","Matter is now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499636,"accession_number":"0001193125-26-228956","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K/A","filed_at":"2026-05-18T20:20:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.","All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.","Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.","8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).","LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":484436,"accession_number":"0001193125-26-228133","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-05-18T13:33:34+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.","Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.","PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.","Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.","Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94512,"accession_number":"0001193125-26-187243","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).","Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.","No assurance given that company will meet MVLS requirement or maintain other listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94511,"accession_number":"0001193125-26-170572","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics appoints June Bray as independent director, expands board to four members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.","Bray is deemed independent and will serve on Nominating & Governance, Audit, and Compensation Committees.","Director compensation: $38,000 annual board retainer plus $7,500 (Nominating & Gov), $5,500 (Audit), $4,000 (Comp); no initial option grant.","Bray will enter the company's standard form of indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94510,"accession_number":"0001193125-26-149021","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 16.3M shares outstanding post-split; ratio 1-for-10.","Certificate of Amendment filed with Delaware on April 9; effective 11:59 PM ET April 10.","Split-adjusted trading on Nasdaq begins at market open April 13; new CUSIP 22053A206.","Stock options and warrants proportionally adjusted; no change to rights or preferences.","Equiniti Trust Company appointed as exchange agent; fractional shares paid in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106948,"accession_number":"0001193125-26-130489","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.","All obligations under the Finance Documents are fully satisfied and discharged.","CEO says settlement removes a substantial constraint on pursuing strategic alternatives.","Company continues restructuring and evaluation of strategic alternatives including M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106947,"accession_number":"0001193125-26-117794","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.","MVLS Notice: market value of listed securities below $50M for 30 consecutive business days; cure by Sept 14, 2026.","To regain compliance, bid price must close at $1+ for 10 consecutive days, or MVLS at $50M+ for 10 consecutive days.","If not cured by deadline, company may transfer to Nasdaq Capital Market or face delisting.","Stock continues trading on Nasdaq under symbol QNCX during cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106946,"accession_number":"0001193125-26-047544","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.","Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.","Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.","Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.","May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106945,"accession_number":"0001193125-26-033758","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Five directors resign from Quince Therapeutics board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.","Resignations were not due to any disagreement with the company on operations, policies, or practices.","CEO Dirk Thye remains as the sole executive officer; no replacements announced.","Company continues under current management; board size reduced from six to one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106944,"accession_number":"0001193125-26-029524","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.","Key secondary endpoint CGI-S also missed (p=0.522).","eDSP well tolerated; most common adverse events pruritis and pyrexia.","Company to cease clinical development of eDSP and explore available options.","Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123283,"accession_number":"0001193125-25-277523","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.","Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.","iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.","Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.","FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123282,"accession_number":"0001193125-25-242514","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.","The statement was based on a different study (EJPN Article), not the IntraBio Phase 2 study; Quince removed it from materials.","The EJPN Article found NALL failed to improve motor function significantly but improved some symptoms (e.g., nausea, constipation).","Quince advises investors not to rely on the retracted statement; underlying facts did not support the original claim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139952,"accession_number":"0001193125-25-220722","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.","1% of 9% deferred interest converted to fixed rate, payable March 31, 2026.","Amendment dated September 25, 2025 under EIB Facility originally July 24, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139951,"accession_number":"0000950170-25-106536","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.","Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.","Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.","Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.","New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139950,"accession_number":"0001193125-25-159886","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.","Powering at ~90% for primary endpoint; trial under FDA Special Protocol Assessment.","Topline results expected Q1 2026; NDA submission planned H2 2026 if positive.","All enrolled participants have elected to transition to open-label extension study.","FDA Fast Track designation and SPA agreement in place for eDSP in Ataxia-Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157570,"accession_number":"0001193125-25-140873","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Quince raises $11.5M in private placement of stock and warrants; management participates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.","Common warrants exercisable at $1.20/share for 5 years; pre-funded warrants exercisable at $0.001/share.","Management investors: CEO Dirk Thye ($200k), COO Brendan Hannah ($50k), President Charles Ryan ($10k).","Company to file resale registration statement within 120 days under Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157569,"accession_number":"0001662774-25-000034","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quince Therapeutics shareholders approve reverse stock split and authorized share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).","Authorized common shares increased from 100M to 250M (27,159,134 for vs 3,776,348 against).","Directors June Bray, Christopher Senner, and Rajiv Patni elected with >85% of votes cast.","BDO USA ratified as independent auditor for FY2025 (30,015,571 for).","Advisory vote on executive compensation passed (16,590,485 for, 800,094 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157568,"accession_number":"0001662774-25-000031","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.","Early enrollment conclusion by end of June would provide ~80% power for primary endpoint.","Cash and investments $31.6M; net loss Q1 2025 of $15.0M ($0.34 per share).","Topline results expected early 2026; NDA/MAA submissions planned H2 2026 if positive.","All 19 study sites activated; slower enrollment cited due to challenging academic site environment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175936,"accession_number":"0001662774-25-000011","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.","Phase 3 NEAT trial enrolled 61 participants (>50%); topline results expected Q4 2025.","Received FDA Fast Track designation (June 2024); Phase 3 ATTeST results published in The Lancet Neurology.","R&D $18.6M, G&A $17.6M; operating cash burn $31.9M includes $5M milestone and $17.1M goodwill impairment.","Appointed Dr. William Whitehouse to SAB; USPTO allowed patent claims extending to 2036 for eDSP in A-T."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192855,"accession_number":"0001662774-24-000013","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quince Therapeutics regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Nov 12, 2024, Nasdaq confirmed Quince regained compliance with $1.00 minimum bid price rule.","Compliance achieved after closing bid price stayed at or above $1.00 for 10 consecutive business days (Oct 29–Nov 11, 2024).","This resolves the non-compliance notice received June 20, 2024, and the matter is closed.","The company was facing potential delisting from Nasdaq Global Select Market if not compliant by Dec 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192854,"accession_number":"0001662774-24-000010","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.","Cash, equivalents, and short-term investments of $47.8M; runway expected into 2026 through topline results.","Net loss of $5.5M ($0.13 per share) for Q3 2024; R&D expenses $4.9M, G&A expenses $3.6M.","Plans to initiate a Phase 2 Duchenne muscular dystrophy study in 2025.","Identified 11 potential new rare disease indications for EryDex beyond A-T and DMD."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209263,"accession_number":"0001662774-24-000004","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.","Net loss $27.7M ($0.64/share) includes $17.1M goodwill impairment; R&D $4.2M, G&A $4.7M.","Phase 3 NEAT enrolled 7 patients; topline results expected Q4 2025; NDA/MAA in 2026 if positive.","FDA Fast Track for EryDex in A-T; diagnosed U.S. patients estimated at ~4,600 (up from ~3,400).","Planning DMD proof-of-concept study in 2025; evaluating partnerships for ex-U.S. rights."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227215,"accession_number":"0001193125-24-165631","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quince Therapeutics receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice for non-compliance with $1.00 minimum bid price requirement.","Closing bid price below $1.00 for 34 consecutive trading days.","Has until December 17, 2024 to regain compliance by closing at $1.00 for 10 consecutive days.","May transfer to Nasdaq Capital Market for additional 180-day compliance period if eligible.","Company will monitor closing bid price; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227214,"accession_number":"0001193125-24-156202","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quince Therapeutics shareholders approve reverse stock split and elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.","Elected Class II directors Dirk Thye, David Lamond, and Luca Benatti to serve until 2027 annual meeting.","Ratified BDO USA as independent registered accounting firm for fiscal year ending Dec 31, 2024.","Advisory say-on-pay approved: 17,945,554 for, 429,833 against, 94,767 abstentions (14,090,117 broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246104,"accession_number":"0001193125-24-037521","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics appoints Rajiv Patni as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajiv Patni appointed to board effective Feb 15, 2024 as Class III director, term through 2025 annual meeting.","Receives $38,000 annual retainer plus 54,000-share stock option grant under 2019 Equity Incentive Plan.","Options vest in equal annual installments over 3 years, exercise price equals Feb 15 closing price.","Entered standard indemnification agreement; no family relationships or related party transactions with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246103,"accession_number":"0001193125-24-018071","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics no salary increase for 2024; option grants to officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No salary increase for executive officers in 2024; Committee approved stock option grants.","CEO Dirk Thye: $302,500 bonus, 1,500,000 options vesting monthly over 4 years.","President Charles Ryan: $70,000 bonus, 145,000 options; COO Brendan Hannah: $178,500 bonus, 600,000 options.","Option grants effective Feb 1, 2024 under 2019 Equity Incentive Plan; vesting over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246101,"accession_number":"0001193125-24-003344","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K/A","filed_at":"2024-01-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Quince provides EryDel historical financials; FY2022 loss of €12.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.","As of Dec 2022, EryDel cash €1.3M, negative equity €16.5M; operating cash flow used €11.3M.","Quince had $83.2M cash at Sep 30, 2023, expected to fund EryDex Phase 3 trial into at least 2026.","Acquisition adds EryDel's Red Cell Loader platform and Phase 3 therapy for Ataxia-Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246102,"accession_number":"0001193125-24-001482","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quince Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Quince on Dec 4, 2023 of non-compliance due to bid price below $1.00 for 30 consecutive days.","On Dec 29, 2023, Nasdaq confirmed compliance after closing bid price ≥ $1.00 for 13 consecutive business days.","The matter is closed; Quince remains listed on the Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263566,"accession_number":"0001193125-23-302116","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Quince Therapeutics terminates exclusive worldwide license for NOV004 bone fracture repair program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination effective October 31, 2023, following prior decision to discontinue internal development of NOV004.","License was exclusive worldwide under Purdue Research Foundation patents related to bone fracture repair.","Quince agreed to reimburse PRF for patent prosecution costs and assign development documents to PRF.","Quince retains internal research rights to assigned documents; PRF must pay Quince 35% if it licenses to certain third parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263565,"accession_number":"0001193125-23-291671","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quince Therapeutics receives Nasdaq bid price deficiency notice; has until June 3, 2024 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 4, 2023 for failing minimum bid price of $1.00 for 30 consecutive trading days.","Has 180 calendar days, until June 3, 2024, to regain compliance by closing bid >=$1.00 for 10 consecutive days.","If not compliant by June 3, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","No immediate effect on listing; company intends to monitor and consider options to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263564,"accession_number":"0001193125-23-264057","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.","Granted option to purchase 75,000 shares at $0.99, vesting over 48 months from Oct 23, 2023.","Served as Chief Business Officer since May 2022; previously COO of Novosteo Inc.","No family relationships or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263563,"accession_number":"0001193125-23-260785","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["1.01","2.01","2.03","5.02","9.01"],"status":"ready","headline":"Quince Therapeutics closes acquisition of EryDel for up to $485M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 6,525,315 shares (15.2% ownership) to EryDel shareholders; up to 725,036 more shares at first anniversary.","Contingent payments up to $485M: $5M development, $25M NDA acceptance, $60M approval, $395M sales milestones.","Guarantees EryDel's EUR 30M EIB facility; ~EUR 10M drawn, maturity Aug 2026, fixed 9% interest.","Appointed Luca Benatti as Class II director; granted option for 54,000 shares vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280773,"accession_number":"0001193125-23-229101","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["1.01","2.03","5.02"],"status":"ready","headline":"Appoints Charles S. Ryan as President; subsidiary issues up to $1M promissory note to EryDel S.p.A.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Promissory note of up to $1.0M to EryDel S.p.A. in two tranches: $500k at 5.07% per annum; second $500k at AFR.","Maturity July 1, 2024; obligations discharged upon closing of Stock Purchase Agreement or termination in certain circumstances.","Charles S. Ryan, Ph.D. appointed President, effective Sept 1, 2023; previously President/CEO of Travecta Therapeutics, CEO of Neurotrope.","Compensation: $500k base salary, up to 40% bonus, option for 545,000 shares vesting over 4 years.","Severance: 12-month salary on qualifying termination; 18-month salary if change of control, plus equity acceleration and health benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280772,"accession_number":"0001193125-23-209172","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics CMO Karen Smith to depart effective Sept 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Karen Smith, M.D., Ph.D. will depart on September 1, 2023.","Separation agreement includes 12 months base salary severance plus prorated 2023 bonus and health benefits lump sum.","Outstanding equity awards subject to 50% accelerated vesting; additional benefits if change in control occurs within 3 months after departure.","Dr. Smith will continue as employee until the departure date under transition and separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280771,"accession_number":"0001193125-23-191839","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Quince Therapeutics to acquire EryDel for up to 7.25M shares + $485M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["EryDel shareholders get up to 7,250,352 shares (16.7% of combined company) and up to $485M in milestone cash payments, no royalties.","Quince assumes EryDel's $13M (€10M) EIB loan; payments start H2 2026.","Preliminary cash, equivalents, and short-term investments of ~$87.6M as of June 30, 2023 to fund operations into 2026.","CMO Karen Smith to depart effective September 1, 2023; Luca Benatti to join board upon closing.","Acquisition includes Phase 3 asset EryDex for Ataxia-Telangiectasia under FDA SPA; close expected Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299393,"accession_number":"0001193125-23-154245","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quince Therapeutics shareholders approve 1-for-10 reverse stock split and elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 1-for-10 reverse stock split: 22.3M votes for, 4.0M against.","Margaret McLoughlin and Una Ryan elected as Class I directors with over 8.1M votes each.","Ratification of BDO USA as auditor for FY2023 approved with 22.9M votes for.","Advisory vote on executive compensation passed with 8.7M votes for, 2.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299392,"accession_number":"0001193125-23-092414","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Quince Therapeutics adopts one-year poison pill after unsolicited bid, share accumulation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan effective immediately, expires April 5, 2024; dividend of one right per share on April 17, 2023.","Trigger at 10% beneficial ownership (15% for passive institutional); exercise price $6.00 per right.","Rights become exercisable if threshold crossed; holders (except triggering party) can buy shares at 2x market value.","Board may redeem rights for $0.001 each before trigger; company retaining financial advisor for strategic alternatives.","Plan adopted in response to unsolicited acquisition proposal and share accumulation by certain investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319555,"accession_number":"0001193125-23-082305","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics director Philip Low resigns from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Philip Low, Ph.D. resigned from the Board effective March 27, 2023.","Departure was not a result of any disagreement with the Company, Board, or management.","No replacement has been announced for the vacant Board seat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319554,"accession_number":"0001193125-23-060044","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ted Monohon resigns as Chief Accounting Officer and VP of Finance, effective March 16, 2023; no disagreement with company.","Brendan Hannah, current Chief Business Officer, appointed as principal financial officer and principal accounting officer effective March 16, 2023.","Hannah's compensation unchanged; no family relationships or reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319553,"accession_number":"0001193125-23-019103","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["2.02","2.05","8.01"],"status":"ready","headline":"Quince Therapeutics cuts workforce 47%; reports $94M cash; pivots to in-licensing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents, and marketable securities of ~$94M as of Dec 31, 2022.","Board approved cost reduction plan cutting headcount by ~47%, expected to save ~$9.5M in annual operating expenses (2023).","Estimated restructuring costs of $0.6M–$0.8M; workforce reduction begins Feb 2023, completes by Apr 2023.","Company to prioritize in-licensing and acquisition of clinical-stage assets for rare diseases; out-license bone-targeting platform NOV004.","Out-licensing of NOV004 to commence immediately; goal to conclude partnership by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319552,"accession_number":"0001193125-23-017549","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.","Royalties: high single-digit to mid-teens on clinical-stage programs; low single-digit on preclinical.","Exclusive option to obtain rights to COR388 for animal health until June 30, 2023.","No salary increases for 2023; executives granted stock options: CEO 600k, others 110k-225k, vesting monthly over 4 years.","2022 bonus payouts: CEO $169,287, CAO $137,185, CMO $116,962, CBO $104,650."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337744,"accession_number":"0001193125-22-307303","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quince Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on Dec 13, 2022: closing bid price below $1.00 for 30 consecutive days.","Initial compliance period until June 12, 2023 to regain bid price ≥$1.00 for 10 days.","If not compliant by June 12, may transfer to Nasdaq Capital Market for second 180-day period.","Failure to cure could result in delisting from Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355118,"accession_number":"0001193125-22-255696","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics director Marwan Sabbagh resigns effective Sept 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marwan Sabbagh resigned from the Board effective September 30, 2022; no disagreement with company.","Board granted accelerated vesting of portion of March 14, 2022 stock option for service period.","Post-termination exercise period for vested stock option extended to 12 months after departure date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355117,"accession_number":"0001193125-22-207867","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","5.03","8.01","9.01"],"status":"ready","headline":"Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).","Name changed from Cortexyme to Quince Therapeutics; ticker changes from CRTX to QNCX effective Aug 1, 2022.","Strategic focus on bone-targeting drug platform and lead molecule NOV004; Phase 1 clinical studies expected in 2023.","Plans to in-license or acquire clinical-stage assets for debilitating/rare diseases and out-license legacy neuroscience assets.","Cash runway expected to fund operations into second half of 2025; corporate restructuring completed in H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355116,"accession_number":"0001193125-22-200068","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cortexyme EVP of R&D Leslie Holsinger resigns effective July 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Holsinger receives $339,000 cash severance (9 months' base salary) in a lump sum.","Health care continuation benefits and 12-month extension of vested equity exercise period provided.","Additional change-in-control severance and accelerated vesting available if a change in control occurs within 3 months post-departure.","Company anticipates entering into a consulting agreement with Dr. Holsinger for transition through year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373213,"accession_number":"0001193125-22-172060","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["1.01","2.03","5.02","5.07"],"status":"ready","headline":"CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.","June Bray appointed as Class III director; receives initial option for 54,000 shares at $3.20, vesting over 3 years.","Ted Monohon, current CAO and VP Finance, designated as principal financial officer; no change in compensation.","Sublease with ICON Clinical Research for 601 Gateway Blvd, SF: term June 18, 2022 to Nov 30, 2023, optional extension; rent $16,692-$17,206/mo.","Annual meeting: elected Lowe and Senner as directors, ratified BDO as auditor, approved say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18908857.391304348,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-10T23:59:59+00:00|373213"}